Monogram Orthopaedics (NASDAQ:MGRM - Get Free Report) is set to issue its quarterly earnings data after the market closes on Tuesday, November 19th. Analysts expect the company to announce earnings of ($0.12) per share for the quarter.
Monogram Orthopaedics (NASDAQ:MGRM - Get Free Report) last announced its quarterly earnings data on Thursday, August 15th. The company reported ($0.11) EPS for the quarter, missing analysts' consensus estimates of ($0.09) by ($0.02). During the same period in the prior year, the company posted ($0.27) earnings per share. On average, analysts expect Monogram Orthopaedics to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.
Monogram Orthopaedics Stock Down 4.5 %
Shares of MGRM stock traded down $0.10 during mid-day trading on Wednesday, reaching $2.12. The stock had a trading volume of 84,493 shares, compared to its average volume of 148,612. The firm's 50 day simple moving average is $2.54 and its 200 day simple moving average is $2.38. Monogram Orthopaedics has a one year low of $1.53 and a one year high of $4.90. The firm has a market cap of $73.54 million, a PE ratio of -6.41 and a beta of 2.28.
Monogram Orthopaedics Company Profile
(
Get Free Report)
Monogram Orthopaedics, Inc focuses on developing a product solution architecture to enable patient-optimized orthopaedic implants. The company intends to produce and market robotic surgical equipment and related software, orthopedic implants, tissue ablation tools, navigation consumables, and other miscellaneous instrumentation for use in reconstructive joint replacement procedures.
Featured Articles
Before you consider Monogram Orthopaedics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Monogram Orthopaedics wasn't on the list.
While Monogram Orthopaedics currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Unlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.